To advance our mission of providing clinical diagnostics to improve patient outcomes SpeeDx collaborate with partners across the diagnostic space. PlexPCR® technology has helped transform infectious disease diagnostics, as well as significantly impacting cancer diagnosis and treatment.
Significant improvements in the diagnosis and treatment of cancer have occurred through a licensing partnership with Biocartis. PlexPCR® drives the market-leading multiplex capability in the Biocartis Idylla™ platform.
SpeeDx partnered with Cepheid as a trusted reagent manufacturer (TRM) under their FleXible Cartridge program, aimed at accelerating menu expansion on the Cepheid GeneXpert systems.
The first test, ResistancePlus® MG FleXible, launched October 2019, detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance.
SpeeDx partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, to expand access to infectious disease and antibiotic resistance tests and technology. Under the terms of the agreement, Roche has non-exclusive access to SpeeDx existing tests and technology for the management of antibiotic resistance in STIs, to quickly bring new products to a broader group of patients around the world.
View Products from Roche:
“QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POC™ platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies.”
“The availability of ResistancePlus® MG in a FleXible cartridge that runs on the GeneXpert® System is a compelling and exciting extension for us.”
"The game-changing real-time PCR based technology uses a unique combination of PlexZyme® and PlexPrime®, which allows very high sensitivity and specificity combined with high multiplexing capability."